The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...

Net profit recorded RMB222.0 million, a significant turnaround from a year ago Adjusted Non-IFRS net profit recorded RMB314.6 million, a YOY increase of nearly 50.6%. SHANGHAI, March 27, 2025 ...

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

Krystal Biotech, Inc. ( (KRYS)) has released its Q3 earnings. Here is a breakdown of the information Krystal Biotech, Inc. presented to its investors. Take advantage of TipRanks Premium at 50% off!

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

Investment giant KKR & Co. Inc. (NYSE: KKR) is advising investors to look past the crowded trades of the U.S. large-cap market for the next phase of growth. In its “High Grading” Outlook for 2026, the ...

Industrial biotechnology at scale focuses on robust processes, high‑volume products, and performance outcomes. This Collection welcomes original research on large‑scale fermentation, process ...

Protagonist Therapeutics is a clinical-stage biotechnology company that uses proprietary peptide technology to address unmet medical needs in hematology and immunology. It focuses on patients with ...